International Journal of Cancer Management

Published by: Kowsar

Lactobacilli Differentially Modulate mTOR and Wnt/ β-Catenin Pathways in Different Cancer Cell Lines

Zahra Taherian-Esfahani 1 , Atieh Abedin-Do 1 , Zahra Nouri 2 , Reza Mirfakhraie 1 , Soudeh Ghafouri-Fard 1 , * and Elahe Motevaseli 3 , **
Authors Information
1 Department of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
2 Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, IR Iran
3 Department of Molecular Medicine, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, IR Iran
Corresponding Authors:
Article information
  • Iranian Journal of Cancer Prevention: June 2016, 9 (3); e5369
  • Published Online: June 15, 2016
  • Article Type: Research Article
  • Received: January 12, 2016
  • Revised: February 9, 2016
  • Accepted: May 18, 2016
  • DOI: 10.17795/ijcp-5369

To Cite: Taherian-Esfahani Z, Abedin-Do A, Nouri Z, Mirfakhraie R, Ghafouri-Fard S, et al. Lactobacilli Differentially Modulate mTOR and Wnt/ β-Catenin Pathways in Different Cancer Cell Lines, Int J Cancer Manag. 2016 ; 9(3):e5369. doi: 10.17795/ijcp-5369.

Abstract
Copyright © 2016, Iranian Journal of Cancer Prevention. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Motevaseli E, Shirzad M, Raoofian R, Hasheminasab SM, Hatami M, Dianatpour M, et al. Differences in vaginal lactobacilli composition of Iranian healthy and bacterial vaginosis infected women: a comparative analysis of their cytotoxic effects with commercial vaginal probiotics. Iran Red Crescent Med J. 2013; 15(3): 199-206[DOI][PubMed]
  • 2. Motevaseli E, Shirzad M, Akrami SM, Mousavi AS, Mirsalehian A, Modarressi MH. Normal and tumour cervical cells respond differently to vaginal lactobacilli, independent of pH and lactate. J Med Microbiol. 2013; 62: 1065-72[DOI][PubMed]
  • 3. Azam R, Ghafouri-Fard S, Tabrizi M, Modarressi MH, Ebrahimzadeh-Vesal R, Daneshvar M, et al. Lactobacillus acidophilus and Lactobacillus crispatus culture supernatants downregulate expression of cancer-testis genes in the MDA-MB-231 cell line. Asian Pac J Cancer Prev. 2014; 15(10): 4255-9[PubMed]
  • 4. Zabihollahi R, Motevaseli E, Sadat SM, Azizi-Saraji AR, Asaadi-Dalaie S, Modarressi MH. Inhibition of HIV and HSV infection by vaginal lactobacilli in vitro and in vivo. Daru. 2012; 20(1): 53[DOI][PubMed]
  • 5. Murosaki S, Muroyama K, Yamamoto Y, Yoshikai Y. Antitumor effect of heat-killed Lactobacillus plantarum L-137 through restoration of impaired interleukin-12 production in tumor-bearing mice. Cancer Immunol Immunother. 2000; 49(3): 157-64[PubMed]
  • 6. Abedin-Do A, Taherian-Esfahani Z, Ghafouri-Fard S, Ghafouri-Fard S, Motevaseli E. Immunomodulatory effects of Lactobacillus strains: emphasis on their effects on cancer cells. Immunotherapy. 2015; 7(12): 1307-29[DOI][PubMed]
  • 7. Ahmadi MA, Ebrahimi MT, Mehrabian S, Tafvizi F, Bahrami H, Dameshghian M. Antimutagenic and anticancer effects of lactic acid bacteria isolated from Tarhana through Ames test and phylogenetic analysis by 16S rDNA. Nutr Cancer. 2014; 66(8): 1406-13[DOI][PubMed]
  • 8. Zhang M, Wang F, Jiang L, Liu R, Zhang L, Lei X, et al. Lactobacillus salivarius REN inhibits rat oral cancer induced by 4-nitroquioline 1-oxide. Cancer Prev Res (Phila). 2013; 6(7): 686-94[DOI][PubMed]
  • 9. Chavez KJ, Garimella SV, Lipkowitz S. Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer. Breast Dis. 2010; 32(1-2): 35-48[DOI][PubMed]
  • 10. Shokrollahi Barough M, Hasanzadeh H, Barati M, Pak F, Kokhaei P, Rezaei-Tavirani M. Apoptosis/Necrosis Induction by Ultraviolet, in ER Positive and ER Negative Breast Cancer Cell Lines. Iran J Cancer Prev. 2015; 8(6)[DOI][PubMed]
  • 11. Adey A, Burton JN, Kitzman JO, Hiatt JB, Lewis AP, Martin BK, et al. The haplotype-resolved genome and epigenome of the aneuploid HeLa cancer cell line. Nature. 2013; 500(7461): 207-11[DOI][PubMed]
  • 12. Motevaseli E, Azam R, Akrami SM, Mazlomy M, Saffari M, Modarressi MH, et al. The Effect of Lactobacillus crispatus and Lactobacillus rhamnosusCulture Supernatants on Expression of Autophagy Genes and HPV E6 and E7 Oncogenes in The HeLa Cell Line. Cell J. 2016; 17(4): 601-7[PubMed]
  • 13. Wang SM, Zhang LW, Fan RB, Han X, Yi HX, Zhang LL, et al. Induction of HT-29 cells apoptosis by lactobacilli isolated from fermented products. Res Microbiol. 2014; 165(3): 202-14[DOI][PubMed]
  • 14. Paplomata E, O'Regan R. The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers. Ther Adv Med Oncol. 2014; 6(4): 154-66[DOI][PubMed]
  • 15. Husseinzadeh N, Husseinzadeh HD. mTOR inhibitors and their clinical application in cervical, endometrial and ovarian cancers: a critical review. Gynecol Oncol. 2014; 133(2): 375-81[DOI][PubMed]
  • 16. Francipane MG, Lagasse E. mTOR pathway in colorectal cancer: an update. Oncotarget. 2014; 5(1): 49-66[DOI][PubMed]
  • 17. Meric-Bernstam F, Gonzalez-Angulo AM. Targeting the mTOR signaling network for cancer therapy. J Clin Oncol. 2009; 27(13): 2278-87[DOI][PubMed]
  • 18. Kang JH. Protein kinase C (PKC) isozymes and cancer. N J Sci. 2014; : 231418
  • 19. Lonne GK, Cornmark L, Zahirovic IO, Landberg G, Jirstrom K, Larsson C. PKCalpha expression is a marker for breast cancer aggressiveness. Mol Cancer. 2010; 9: 76[DOI][PubMed]
  • 20. Wang W, Xue L, Liu H, Wang P, Xu P, Cai Y. Aberrant changes of Wnt2/beta-catenin signaling pathway induced by sodium nitroprusside in human esophageal squamous cell carcinoma cell lines. Cancer Invest. 2010; 28(3): 230-41[DOI][PubMed]
  • 21. Chang E, Park DI, Kim YJ, Kim BK, Park JH, Kim HJ, et al. Detection of colorectal neoplasm using promoter methylation of ITGA4, SFRP2, and p16 in stool samples: a preliminary report in Korean patients. Hepatogastroenterology. 2010; 57(101): 720-7[PubMed]
  • 22. Chung MT, Sytwu HK, Yan MD, Shih YL, Chang CC, Yu MH, et al. Promoter methylation of SFRPs gene family in cervical cancer. Gynecol Oncol. 2009; 112(2): 301-6[DOI][PubMed]
  • 23. Veeck J, Noetzel E, Bektas N, Jost E, Hartmann A, Knuchel R, et al. Promoter hypermethylation of the SFRP2 gene is a high-frequent alteration and tumor-specific epigenetic marker in human breast cancer. Mol Cancer. 2008; 7: 83[DOI][PubMed]
  • 24. Luu HH, Zhang R, Haydon RC, Rayburn E, Kang Q, Si W, et al. Wnt/beta-catenin signaling pathway as a novel cancer drug target. Curr Cancer Drug Targets. 2004; 4(8): 653-71[PubMed]
  • 25. Wang T, Li Y, Wang W, Tuerhanjiang A, Wu Z, Yang R, et al. Twist2, the key Twist isoform related to prognosis, promotes invasion of cervical cancer by inducing epithelial-mesenchymal transition and blocking senescence. Hum Pathol. 2014; 45(9): 1839-46[DOI][PubMed]
  • 26. Li J, Wang CY. TBL1-TBLR1 and beta-catenin recruit each other to Wnt target-gene promoter for transcription activation and oncogenesis. Nat Cell Biol. 2008; 10(2): 160-9[DOI][PubMed]
  • 27. Polakis P. Wnt signaling and cancer. Genes Dev. 2000; 14(15): 1837-51[PubMed]
  • 28. Esfandiary A, Taherian-Esfahani Z, Abedin-Do A, Mirfakhraie R, Shirzad M, Ghafouri-Fard S, et al. Lactobacilli Modulate Hypoxia-Inducible Factor (HIF)-1 Regulatory Pathway in Triple Negative Breast Cancer Cell Line. Yakhteh. 2016; 18(2)
  • 29. Zare-Mirakabadi A, Sarzaeem A, Moradhaseli S, Sayad A, Negahdary M. Necrotic Effect versus Apoptotic Nature of Camptothecin in Human Cervical Cancer Cells. Iran J Cancer Prev. 2012; 5(3): 109-16[PubMed]
  • 30. Nouri Z, Karami F, Neyazi N, Modarressi MH, Karimi R, Khorramizadeh MR. Dual anti-metastatic and anti-proliferative activity assessment of two probiotics on HeLa and HT-29 cell lines. Yakhteh. 2016; 18(2): 127-34
  • 31. Ballou LM, Lin RZ. Rapamycin and mTOR kinase inhibitors. J Chem Biol. 2008; 1(1-4): 27-36[DOI][PubMed]
  • 32. Chung MT, Lai HC, Sytwu HK, Yan MD, Shih YL, Chang CC, et al. SFRP1 and SFRP2 suppress the transformation and invasion abilities of cervical cancer cells through Wnt signal pathway. Gynecol Oncol. 2009; 112(3): 646-53[DOI][PubMed]
  • 33. Li Y, Wei J, Xu C, Zhao Z, You T. Prognostic significance of cyclin D1 expression in colorectal cancer: a meta-analysis of observational studies. PLoS One. 2014; 9(4)[DOI][PubMed]
  • 34. Mori Y, Olaru AV, Cheng Y, Agarwal R, Yang J, Luvsanjav D, et al. Novel candidate colorectal cancer biomarkers identified by methylation microarray-based scanning. Endocr Relat Cancer. 2011; 18(4): 465-78[DOI][PubMed]
  • 35. Safaei A, Sobhi S, Rezaei-Tavirani M, Zali MR. Genomic and epigenetic instability in colorectal cancer. Iran J Cancer Prevent. 2013; 6: 54-63
  • 36. Wang J, Ou J, Guo Y, Dai T, Li X, Liu J, et al. TBLR1 is a novel prognostic marker and promotes epithelial-mesenchymal transition in cervical cancer. Br J Cancer. 2014; 111(1): 112-24[DOI][PubMed]
  • 37. Bae DS, Cho SB, Kim YJ, Whang JD, Song SY, Park CS, et al. Aberrant expression of cyclin D1 is associated with poor prognosis in early stage cervical cancer of the uterus. Gynecol Oncol. 2001; 81(3): 341-7[DOI][PubMed]
  • 38. Uren A, Fallen S, Yuan H, Usubutun A, Kucukali T, Schlegel R, et al. Activation of the canonical Wnt pathway during genital keratinocyte transformation: a model for cervical cancer progression. Cancer Res. 2005; 65(14): 6199-206[DOI][PubMed]
  • 39. Rampias T, Boutati E, Pectasides E, Sasaki C, Kountourakis P, Weinberger P, et al. Activation of Wnt signaling pathway by human papillomavirus E6 and E7 oncogenes in HPV16-positive oropharyngeal squamous carcinoma cells. Mol Cancer Res. 2010; 8(3): 433-43[DOI][PubMed]
  • 40. Veeck J, Bektas N, Hartmann A, Kristiansen G, Heindrichs U, Knuchel R, et al. Wnt signalling in human breast cancer: expression of the putative Wnt inhibitor Dickkopf-3 (DKK3) is frequently suppressed by promoter hypermethylation in mammary tumours. Breast Cancer Res. 2008; 10(5)[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments